Risk factors associated with Clostridium difficile infection after kidney and pancreas transplantation

Transplant Infectious Disease

Volumn 15, Issue 5, 2013, Pages 502-509

  Shah, S A ^a   Tsapepas, D S ^a   Kubin, C J ^a,b   Martin, S T ^a   Mohan, S ^b   Ratner, L E ^b   Pereira, M ^b   Kapur, S ^c   Dadhania, D ^c   Walker Mcdermott, J K ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile infection; Kidney transplantation; Pancreas transplantation; Solid organ transplantation

Indexed keywords

ACICLOVIR; AZTREONAM; BASILIXIMAB; CEFAZOLIN; CEPHALOSPORIN; CLINDAMYCIN; CLOTRIMAZOLE; COTRIMOXAZOLE; DAPSONE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIINFECTIVE AGENT;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; GRAFT RECIPIENT; GRAFT REJECTION; INFECTIOUS COMPLICATION; KIDNEY PANCREAS TRANSPLANTATION; LEUKOPENIA; PRIORITY JOURNAL; RISK FACTOR; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; ALLOGRAFT; CASE CONTROL STUDY; CLOSTRIDIUM INFECTIONS; COMPLICATION; CROSS INFECTION; DIARRHEA; FEMALE; HUMAN; INCIDENCE; ISOLATION AND PURIFICATION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; PEPTOCLOSTRIDIUM DIFFICILE; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOGRAFTS; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; FEMALE; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84884973149     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12113     Document Type: Article

References (29)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31 (5): 431-455.
2. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365 (18): 1693-1703.
3. Keven K, Basu A, Re L, et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis 2004; 6 (1): 10-14.
4. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353 (23): 2433-2441.
5. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353 (23): 2442-2449.
6. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994; 15 (6): 371-381.
7. Dubberke ER, Riddle DJ. Clostridium difficile in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S35-S40.
8. Riddle DJ, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13 (6): 592-600.
9. Stelzmueller I, Goegele H, Biebl M, et al. Clostridium difficile colitis in solid organ transplantation-a single-center experience. Dig Dis Sci 2007; 52 (11): 3231-3236.
10. West M, Pirenne J, Chavers B, et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant 1999; 13 (4): 318-323.
11. Niemczyk M, Leszczyniski P, Wyzgal J, Paczek L, Krawczyk M, Luczak M Infections caused by clostridium difficile in kidney or liver graft recipients. Ann Transplant 2005; 10 (2): 70-74.
12. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38 (6): 2386-2388.
13. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40 (1): 1-15.
14. Stanley JD, Burns RP. Clostridium difficile and the surgeon. Am Surg 2010; 76 (3): 235-244.
15. Selinger CP, Greer S, Sutton CJ. Is gastrointestinal endoscopy a risk factor for Clostridium difficile associated diarrhea? Am J Infect Control 2010; 38 (7): 581-582.
16. Gourevitch D, Hawkey P. Clostridium difficile infection and surgery. Br J Surg 2009; 96 (1): 3-4.
17. Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt) 2007; 8 (6): 557-566.
18. Wren SM, Ahmed N, Jamal A, Safadi BY. Preoperative oral antibiotics in colorectal surgery increase the rate of Clostridium difficile colitis. Arch Surg 2005; 140 (8): 752-756.
19. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004; 78 (1): 136-141.
20. Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant 2009; 9 (8): 1816-1825.
21. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24 (3): 324-333.
22. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40 (11): 1591-1597.
23. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45 (3): 302-307.
24. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271 (24): 1913-1918.
25. US Food and Drug Administration. "FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs)." US Department of Health and Human Services. FDA, 2012. Available at http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm (accessed 9 May 2012).
26. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171 (1): 33-38.
27. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31 (4): 1012-1017.
28. Snydman DR. The safety of probiotics. Clin Infect Dis 2008; 46 (Suppl 20): S104-S111; discussion S44-51.
29. Segarra-Newnham M. Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother 2007; 41 (7): 1212-1221.